Your browser doesn't support javascript.
loading
Analytical Validation of Aptamer-Based Serum Vancomycin Monitoring Relative to Automated Immunoassays.
Liu, Yu; Mack, John O; Shojaee, Maryam; Shaver, Alexander; George, Ankitha; Clarke, William; Patel, Neel; Arroyo-Currás, Netzahualcóyotl.
Afiliación
  • Liu Y; ZiO Health Ltd., The Tower, St George Wharf, London SW82BW, U.K.
  • Mack JO; Biochemistry, Cellular and Molecular Biology Program, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
  • Shojaee M; ZiO Health Ltd., The Tower, St George Wharf, London SW82BW, U.K.
  • Shaver A; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
  • George A; ZiO Health Ltd., The Tower, St George Wharf, London SW82BW, U.K.
  • Clarke W; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
  • Patel N; ZiO Health Ltd., The Tower, St George Wharf, London SW82BW, U.K.
  • Arroyo-Currás N; Biochemistry, Cellular and Molecular Biology Program, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
ACS Sens ; 9(1): 228-235, 2024 01 26.
Article en En | MEDLINE | ID: mdl-38110361
ABSTRACT
The practice of monitoring therapeutic drug concentrations in patient biofluids can significantly improve clinical outcomes while simultaneously minimizing adverse side effects. A model example of this practice is vancomycin dosing in intensive care units. If dosed correctly, vancomycin can effectively treat methicillin-resistant streptococcus aureus (MRSA) infections. However, it can also induce nephrotoxicity or fail to kill the bacteria if dosed too high or too low, respectively. Although undeniably important to achieve effectiveness, therapeutic drug monitoring remains inconvenient in practice due primarily to the lengthy process of sample collection, transport to a centralized facility, and analysis using costly instrumentation. Adding to this workflow is the possibility of backlogs at centralized clinical laboratories, which is not uncommon and may result in additional delays between biofluid sampling and concentration measurement, which can negatively affect clinical outcomes. Here, we explore the possibility of using point-of-care electrochemical aptamer-based (E-AB) sensors to minimize the time delay between biofluid sampling and drug measurement. Specifically, we conducted a clinical agreement study comparing the measurement outcomes of E-AB sensors to the benchmark automated competitive immunoassays for vancomycin monitoring in serum. Our results demonstrate that E-ABs are selective for free vancomycin─the active form of the drug, over total vancomycin. In contrast, competitive immunoassays measure total vancomycin, including both protein-bound and free drug. Accounting for these differences in a pilot study consisting of 85 clinical samples, we demonstrate that the E-AB vancomycin measurement achieved a 95% positive correlation rate with the benchmark immunoassays. Therefore, we conclude that E-AB sensors could provide clinically useful stratification of patient samples at trough sampling to guide effective vancomycin dose recommendations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Estreptocócicas / Vancomicina Límite: Humans Idioma: En Revista: ACS Sens Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Estreptocócicas / Vancomicina Límite: Humans Idioma: En Revista: ACS Sens Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos